



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Secretary

September 26, 2012

Phillip A. Proger
Jones Day
51 Louisiana Avenue, N.W.
Washington, D.C. 20001-2113

Re: Yasmin/Yaz, FTC File No. 091-0029

Dear Mr. Proger:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether Bayer Schering Pharma AG, Barr Laboratories, Inc., or others engaged in any unfair methods of competition that violate Section 5 of the Federal Trade Commission Act, 15 U.S.C. § 45, as amended, by entering into agreements regarding any drospirenone/ethinyl estradiol oral contraceptive products.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

Donald S. Clark
Secretary